Skip to main content
. 2021 Jun 2;7(6):1009–1018. doi: 10.1021/acscentsci.1c00010

Figure 5.

Figure 5

Binding of SARS-CoV-2 RBD pretreated with GAGs to Vero-E6 cells. (A) (top to bottom) Untreated RBD, HA (250 μg/mL), UFH (10 μg/mL), NACH (10 μg/mL), and octasaccharide 93 (100 μg/mL), complete dilution series are shown in Figure S7 and Figure S8. (B) ACE2 antibody pretreated with GAGs.

HHS Vulnerability Disclosure